Annals of Vascular Surgery
Volume 21, Issue 1 , Pages 50-55 , January 2007

Low Molecular Weight Heparin Suppresses Tumor Necrosis Factor Expression from Deep Vein Thrombosis

  • John Alfred Carr, MD, FCCP

      Affiliations

    • Department of Cardiothoracic Surgery, University of Chicago, Chicago, IL
    • ,
  • Jae-Sung Cho, MD, FACS

      Affiliations

    • Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
    • Corresponding Author InformationCorrespondence to: Jae-Sung Cho, MD, Division of Vascular Surgery, University of Pittsburgh Medical Center, PUH A1011, 200 Lothrop Street, Pittsburgh, PA 15213, USA

References 

  1. Cho JS, Ouriel KS. Differential thrombogenicity of artery and vein: the role of von Willebrand factor. Ann Vasc Surg. 1995;9:60–70
  2. Wakefield TW, Strieter RM, Wilke CA, et al. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:258–268
  3. Downing LJ, Strieter RM, Kadell AM, et al. Neutrophils are the initial cell type identified in deep venous thrombosis induced vein wall inflammation. ASAIO J. 1996;42:M677–M682
  4. Downing LJ, Wakefield TW, Strieter RM, et al. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J Vasc Surg. 1997;25:816–828
  5. Wakefield TW, Strieter RM, Downing LJ, et al. P-selectin and TNF inhibition reduce venous thrombosis inflammation. J Surg Res. 1996;64:26–31
  6. Norman KE, Moore KL, McEver RP, Ley K. Leukocyte rolling in vivo is mediated by P-selectin glycoprotein ligand-1. Blood. 1995;86:4417–4421
  7. Chamorro A, Cervera A, Castillo J, Davalos A, Aponte JJ, Planas A. Unfractionated heparin is associated with a lower rise of serum vascular cell adhesion molecule-1 in acute ischemic stroke patients. Neurosci Lett. 2002;328:229–232
  8. Manduteanu I, Voinea M, Capraru M, Dragomir E, Simionescu M. A novel attribute of enoxaparin: inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules. Pharmacology. 2002;65:32–37
  9. Wan MX, Zhang XW, Torkvist L, Thorlacius H. Low molecular weight heparin inhibits tumor necrosis factor alpha-induced leukocyte rolling. Inflamm Res. 2001;50:581–584
  10. Wan JG, Mu JS, Zhu HS, Geng JG. N-Desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo. Inflamm Res. 2002;51:435–443
  11. Eriksson BI, Carlsson S, Halvarsson M, Risberg B, Mattsson C. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low molecular weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost. 1997;78:1404–1407
  12. Schumacher WA, Heran CL, Steinbacher TE. Low-molecular weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. J Cardiovasc Pharmacol. 1996;28:19–25
  13. Kitamura N, Yamaguchi M, Shimabukuro K, Miyasaka M, Nakano H, Kumada K. Heparin-like glycosaminoglycans inhibit leukocyte adhesion to endotoxin-activated human vascular endothelial cells under nonstatic conditions. Eur Surg Res. 1996;28:428–435
  14. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood. 1993;82:3253–3258
  15. Downing LJ, Strieter RM, Kadell AM, Wilke C, Greenfield LJ, Wakefield TW. Low-dose low-molecular weight heparin is anti-inflammatory during venous thrombosis. J Vasc Surg. 1998;28:848–854
  16. Weyl A, Vanscheidt W, Weiss JM, Peschen M, Schopf E, Simon J. Expression of the adhesion molecules ICAM-1, VCAM-1, and E-selectin and their ligands VLA-4 and LFA-1 in chronic venous leg ulcers. J Am Acad Dermatol. 1996;34:418–423
  17. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O sulfation and are mediated by blockade of L- and P-selectin. J Clin Invest. 2002;110:127–136
  18. Butcher EC. Leukocyte-endothelial cell recognition: 3 or more steps to specificity and diversity. Cell. 1991;67:1033–1036
  19. Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA. Two distinct monokines, interleukin-1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol. 1986;136:1680–1687
  20. Mantovani A, Dejana E. Cytokines as communication signals between leukocytes and endothelial cells. Immunol. Today 1989;10:370–375
  21. Cahalon L, Lider O, Schor H, Avron A, Gilat D, Hershkoviz R. Heparin disaccharides inhibit tumor necrosis factor production by macrophages and arrest immune inflammation in rodents. Int Immunol. 1997;9:1517–1522
  22. Hartmann G, Krug A, Waller-Fontaine K, Endres S. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin. Mol Med. 1996;2:429–438
  23. Wakefield TW, Strieter RM, Prince MR, Downing LJ, Greenfield LJ. Pathogenesis of venous thrombosis: a new insight. Cardiovasc Surg. 1997;5:6–15
  24. Taheri SA, Lazar L, Haddad G, Castaldo R, Wilson M, Mousa S. Diagnosis of deep venous thrombosis by use of soluble necrosis factor receptor. Angiology. 1998;49:537–541

PII: S0890-5096(06)00025-2

doi: 10.1016/j.avsg.2006.07.003

Annals of Vascular Surgery
Volume 21, Issue 1 , Pages 50-55 , January 2007

Article Tools

* Image Usage & Resolution